Start Codon closes new £15m venture for life science innovation

Start Codon, a life science and healthcare business accelerator based in Cambridge, today announced it has closed Start Codon Fund I LP at £15 million. The fund will be used to support Start Codon’s offering to start-ups, which includes a minimum of £250,000 seed funding, business support services, expert guidance, and access to office and lab facilities. Limited partner investors in the Fund include Novartis International and Cambridge Innovation Capital.

In addition to their investment in the fund, Novartis will work with Start Codon and its founders to select technologies and entrepreneurs to join the Start Codon business acceleration programme, which aims to translate early-stage research into successful companies, ready for funding and partnership. Novartis will also provide support and mentoring to the founders of the start-up companies, and opportunities for partnering as their research evolves.

Founded in 2019 with investment and support from Genentech, a member of the Roche Group, Cambridge Innovation Capital, the Babraham Research Campus through Babraham Bioscience Technologies, Dr Jonathan Milner and Dr Ian Tomlinson, Start Codon plans to invest in and support up to 50 start-up companies over the next five years. Start Codon showcased its first cohort of companies in June and recently enrolled its second cohort of start-ups.

Dr Anstey, partner at Cambridge Innovation Capital, said: “This venture fund will provide start-ups with the opportunity to kick start their development and will bring novel and innovative ideas to commercialisation. We are delighted to have supported Start Codon since its inception and are excited to see it act as an important facilitator in creating success in Cambridge and throughout the UK.”

Dr Jason Mellad, co-founder and chief executive at Start Codon.

Dr Jason Mellad, co-founder and chief executive at Start Codon, said: “This venture fund is part of our strategy to provide our entrepreneurs with the funding they need for start-up costs, such as in-licencing of IP, recruitment, and proof of concept studies. In addition, we provide the opportunity to network and learn from the most successful industry leaders in our sector. With both Genentech and Novartis on board to support our cohort companies in their development, and potentially provide opportunities for commercial partnerships in the future, we are extremely well-positioned to nurture and commercialise the next generation of world-class healthcare companies, which we hope will positively impact many patient’s lives.”

Start Codon is accepting applications for its next cohort of companies and early stage start-up companies in the life sciences and healthcare space are invited to apply here.

Date published: November 16, 2020

Subscriber content

To get unlimited access subscribe today


Already a subscriber? Login